Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026?
11:46am, Thursday, 18'th Dec 2025
Mirum's Livmarli sales surge 70% in the first nine months of 2025. Expanding approvals and commercialization are set to fuel revenue momentum into 2026.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00pm, Wednesday, 10'th Dec 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (NASDAQ:MIRM) & BioAtla (NASDAQ:BCAB) Financial Comparison
01:46am, Wednesday, 10'th Dec 2025
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and BioAtla (NASDAQ: BCAB - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based
Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript
04:17pm, Monday, 08'th Dec 2025
Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript
Mirum Pharma to buy Bluejay Therapeutics for up to $820 million
08:05am, Monday, 08'th Dec 2025
Mirum Pharmaceuticals said on Monday it will acquire Bluejay Therapeutics in a deal worth up to $820 million, adding a late-stage experimental drug for a severe liver disease to its portfolio.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics,
Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 04'th Dec 2025
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026
06:30am, Wednesday, 03'rd Dec 2025
Mirum Pharmaceuticals has been a big winner in 2025 thanks to the success of its flagship product, Livmarli. Livmarli should continue to gain momentum in 2026.
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
04:23pm, Tuesday, 02'nd Dec 2025
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
11:16am, Tuesday, 02'nd Dec 2025
Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clin
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:02pm, Tuesday, 25'th Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the
AXQ Capital LP Invests $290,000 in Mirum Pharmaceuticals, Inc. $MIRM
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) during the second quarter, according to its most recent filing with the SEC. The firm purchased 5,695 shares of the c
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00pm, Monday, 10'th Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharma Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®.
